- recruitingPHASE1
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
This study is testing a new drug, AVA6000, for people with advanced solid tumours like breast, ovarian, or salivary gland cancer. It aims to find a safe dose and see how well it works when standard treatments may no longer be effective.
United States · United Kingdom - recruitingPHASE2
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
This study is looking at a new treatment called HER3-DXd for people with certain advanced solid tumours that haven't responded to other treatments. It aims to see how well it works and if it's safe for different types of cancer, like melanoma, lung cancer, and breast cancer.
United States · Australia · Belgium - authorisedPhase I and Phase II (Integrated)- Other
OVACURE-2: Adoptive T cell therapy plus low dose IL-2 (IL-2ld) as first line neoadjuvant therapy in patients with stage III/IV ovarian cancer
This study looks at a new treatment called adoptive T cell therapy, combined with a low dose of a medicine called IL-2, for women with advanced ovarian cancer. It's an early-stage study testing how safe this treatment is.
Netherlands